HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pharmacology770 papers

Hepatocellular liver damage

Last edited: 4/14/2026

Overview

Hepatocellular liver damage refers to injury primarily affecting liver cells, often due to toxic exposures, drug metabolism issues, or environmental factors. It can manifest from various etiologies including chemical toxins, herbal supplements, and certain medications 13581018.

Diagnosis

  • Clinical Presentation: Elevated liver enzymes (ALT, AST), jaundice, abdominal pain 610.
  • Laboratory Tests: Liver function tests (LFTs), including bilirubin, albumin, and prothrombin time 6.
  • Imaging: Ultrasound or MRI to assess liver structure and rule out other causes 10.
  • Causality Assessment: Use of causality scales like CIOMS/RUCAM and Naranjo for herbal hepatotoxicity 141516.
  • Toxicology Screening: Evaluate for specific toxins or drug metabolites in cases of suspected drug-induced hepatotoxicity 31120.

    • Management

  • Discontinue Trigger: Immediately stop the suspected causative agent 161328.
  • Supportive Care: Fluid management, nutritional support, and monitoring for complications 29.
  • Specific Treatments: Vitamin C supplementation shown to mitigate certain hepatotoxicities (e.g., DEN-induced) 7.
  • Monitoring: Regular LFTs to assess recovery and detect progression 610.
  • Immunosuppression: Consider in severe cases or those with immune-mediated mechanisms, though protocols are evolving 2.
  • Liver Support: In severe cases, consider liver transplantation or other advanced supportive measures 29.

    • Special Populations

  • Pediatrics: Increased vigilance with medications like amoxicillin-clavulanic acid, which can cause hepatotoxicity 13.
  • Elderly: Higher susceptibility to drug-induced hepatotoxicity due to altered pharmacokinetics 17.
  • Comorbidities: Patients with pre-existing liver conditions are at higher risk for severe outcomes 17.

    • Key Recommendations

  • Regular Monitoring of Liver Function: Implement periodic LFTs for patients on hepatotoxic medications, especially in the first 6 months 6 (Evidence: Moderate).
  • Immediate Cessation of Suspected Agents: Discontinue any suspected hepatotoxic agent upon clinical suspicion of liver injury 1613 (Evidence: Strong).
  • Use of Causality Assessment Tools: Employ validated causality assessment scales for accurate attribution of hepatotoxicity to specific agents 1415 (Evidence: Moderate).
  • Consider Supportive Therapies: Provide supportive care including hydration and nutritional support in managing hepatotoxicity 29 (Evidence: Weak).
  • Enhanced Surveillance for Dietary Supplements: Strengthen post-marketing surveillance for hepatotoxicity associated with herbal and dietary supplements 1820 (Evidence: Expert opinion).

    • References

    1 Fareed MM, Khalid H, Khalid S, Shityakov S. Deciphering Molecular Mechanisms of Carbon Tetrachloride- Induced Hepatotoxicity: A Brief Systematic Review. Current molecular medicine 2024. link 2 Jagadisan B, Dhawan A. Adeno-associated viral vector gene therapy: Challenges for the paediatric hepatologist. Journal of pediatric gastroenterology and nutrition 2024. link 3 Moriyama A, Ueda H, Narumi K, Asano S, Furugen A, Saito Y et al.. Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: in vitro and pharmacoepidemiological approaches. Expert opinion on drug metabolism & toxicology 2024. link 4 Chen X, Roberts R, Liu Z, Tong W. A generative adversarial network model alternative to animal studies for clinical pathology assessment. Nature communications 2023. link 5 Britza SM, Musgrave IF, Byard RW. Implications for herbal polypharmacy: coumarin-induced hepatotoxicity increased through common herbal phytochemicals astragaloside IV and atractylenolide I. Toxicology mechanisms and methods 2022. link 6 Imai S, Nasuhara Y, Momo K, Oki H, Kashiwagi H, Sato Y et al.. Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database. Biological & pharmaceutical bulletin 2021. link 7 Son YS, Ullah HMA, Elfadl AK, Chung MJ, Ghim SG, Kim YD et al.. Preventive Effects of Vitamin C on Diethylnitrosamine-induced Hepatotoxicity in . In vivo (Athens, Greece) 2018. link 8 Roytman MM, Poerzgen P, Navarro V. Botanicals and Hepatotoxicity. Clinical pharmacology and therapeutics 2018. link 9 Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC medicine 2016. link 10 Everds NE. Evaluation of clinical pathology data: correlating changes with other study data. Toxicologic pathology 2015. link 11 Jessurun N, van Puijenbroek E. Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database. Drug safety 2015. link 12 Teschke R, Eickhoff A, Wolff A, Frenzel C, Schulze J. Herbal hepatotoxicity and WHO global introspection method. Annals of hepatology 2013. link 13 Hita EO, García JA, Gonzalez JC, Molina AA, Cordero MA, Escobar JS et al.. Amoxicillin-clavulanic acid hepatotoxicity in children. Journal of pediatric gastroenterology and nutrition 2012. link 14 Miljkovic MM, Dobric S, Dragojevic-Simic V. Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity. Journal of clinical pharmacy and therapeutics 2012. link 15 Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality?. Pharmacoepidemiology and drug safety 2011. link 16 Miljkovic MM, Dobric S, Dragojevic-Simic V. Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. Pharmacoepidemiology and drug safety 2011. link 17 Petronijevic M, Ilic K, Suzuki A. Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database. Pharmacoepidemiology and drug safety 2011. link 18 Lobb A. Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World journal of gastroenterology 2009. link 19 Stohs SJ, Preuss HG, Ohia SE, Kaats GR, Keen CL, Williams LD et al.. No evidence demonstrating hepatotoxicity associated with hydroxycitric acid. World journal of gastroenterology 2009. link 20 Navarro VJ. Herbal and dietary supplement hepatotoxicity. Seminars in liver disease 2009. link 21 Chen Y, Guo JJ, Healy DP, Lin X, Patel NC. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. The Annals of pharmacotherapy 2008. link 22 Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug safety 2007. link 23 Hauben M, Vegni F, Reich L, Younus M. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis. European journal of gastroenterology & hepatology 2007. link 24 Griffin JM, Lipscomb JC, Pumford NR. Covalent binding of trichloroethylene to proteins in human and rat hepatocytes. Toxicology letters 1998. link00038-1) 25 Wade LT, Kenna JG, Caldwell J. Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chemical research in toxicology 1997. link 26 Kondo F, Matsumoto H, Yamada S, Ishikawa N, Ito E, Nagata S et al.. Detection and identification of metabolites of microcystins formed in vivo in mouse and rat livers. Chemical research in toxicology 1996. link 27 Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. The Journal of urology 1996. link 28 Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and nonfatal hepatotoxicity associated with flutamide. Annals of internal medicine 1993. link 29 Jennings PE, Blandford RL, Rosenthal FD. Acute sulphasalazine hepatotoxicity. Postgraduate medical journal 1986. link 30 Bove KE, Kosmetatos N, Wedig KE, Frank DJ, Whitlatch S, Saldivar V et al.. Vasculopathic hepatotoxicity associated with E-Ferol syndrome in low-birth-weight infants. JAMA 1985. link

    Original source

    1. [1]
      Deciphering Molecular Mechanisms of Carbon Tetrachloride- Induced Hepatotoxicity: A Brief Systematic Review. — Fareed MM, Khalid H, Khalid S, Shityakov S Current molecular medicine (2024)
    2. [2]
      Adeno-associated viral vector gene therapy: Challenges for the paediatric hepatologist. — Jagadisan B, Dhawan A Journal of pediatric gastroenterology and nutrition (2024)
    3. [3]
      Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: in vitro and pharmacoepidemiological approaches. — Moriyama A, Ueda H, Narumi K, Asano S, Furugen A, Saito Y et al. Expert opinion on drug metabolism & toxicology (2024)
    4. [4]
      A generative adversarial network model alternative to animal studies for clinical pathology assessment. — Chen X, Roberts R, Liu Z, Tong W Nature communications (2023)
    5. [5]
      Implications for herbal polypharmacy: coumarin-induced hepatotoxicity increased through common herbal phytochemicals astragaloside IV and atractylenolide I. — Britza SM, Musgrave IF, Byard RW Toxicology mechanisms and methods (2022)
    6. [6]
      Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database. — Imai S, Nasuhara Y, Momo K, Oki H, Kashiwagi H, Sato Y et al. Biological & pharmaceutical bulletin (2021)
    7. [7]
      Preventive Effects of Vitamin C on Diethylnitrosamine-induced Hepatotoxicity in — Son YS, Ullah HMA, Elfadl AK, Chung MJ, Ghim SG, Kim YD et al. In vivo (Athens, Greece) (2018)
    8. [8]
      Botanicals and Hepatotoxicity. — Roytman MM, Poerzgen P, Navarro V Clinical pharmacology and therapeutics (2018)
    9. [9]
      Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. — Onakpoya IJ, Heneghan CJ, Aronson JK BMC medicine (2016)
    10. [10]
      Evaluation of clinical pathology data: correlating changes with other study data. — Everds NE Toxicologic pathology (2015)
    11. [11]
      Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database. — Jessurun N, van Puijenbroek E Drug safety (2015)
    12. [12]
      Herbal hepatotoxicity and WHO global introspection method. — Teschke R, Eickhoff A, Wolff A, Frenzel C, Schulze J Annals of hepatology (2013)
    13. [13]
      Amoxicillin-clavulanic acid hepatotoxicity in children. — Hita EO, García JA, Gonzalez JC, Molina AA, Cordero MA, Escobar JS et al. Journal of pediatric gastroenterology and nutrition (2012)
    14. [14]
      Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity. — Miljkovic MM, Dobric S, Dragojevic-Simic V Journal of clinical pharmacy and therapeutics (2012)
    15. [15]
      Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? — Teschke R, Schmidt-Taenzer W, Wolff A Pharmacoepidemiology and drug safety (2011)
    16. [16]
      Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. — Miljkovic MM, Dobric S, Dragojevic-Simic V Pharmacoepidemiology and drug safety (2011)
    17. [17]
      Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database. — Petronijevic M, Ilic K, Suzuki A Pharmacoepidemiology and drug safety (2011)
    18. [18]
      Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. — Lobb A World journal of gastroenterology (2009)
    19. [19]
      No evidence demonstrating hepatotoxicity associated with hydroxycitric acid. — Stohs SJ, Preuss HG, Ohia SE, Kaats GR, Keen CL, Williams LD et al. World journal of gastroenterology (2009)
    20. [20]
      Herbal and dietary supplement hepatotoxicity. — Navarro VJ Seminars in liver disease (2009)
    21. [21]
      Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. — Chen Y, Guo JJ, Healy DP, Lin X, Patel NC The Annals of pharmacotherapy (2008)
    22. [22]
      Telithromycin use and spontaneous reports of hepatotoxicity. — Dore DD, DiBello JR, Lapane KL Drug safety (2007)
    23. [23]
      Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis. — Hauben M, Vegni F, Reich L, Younus M European journal of gastroenterology & hepatology (2007)
    24. [24]
      Covalent binding of trichloroethylene to proteins in human and rat hepatocytes. — Griffin JM, Lipscomb JC, Pumford NR Toxicology letters (1998)
    25. [25]
      Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. — Wade LT, Kenna JG, Caldwell J Chemical research in toxicology (1997)
    26. [26]
      Detection and identification of metabolites of microcystins formed in vivo in mouse and rat livers. — Kondo F, Matsumoto H, Yamada S, Ishikawa N, Ito E, Nagata S et al. Chemical research in toxicology (1996)
    27. [27]
      Flutamide hepatotoxicity. — Wysowski DK, Fourcroy JL The Journal of urology (1996)
    28. [28]
      Fatal and nonfatal hepatotoxicity associated with flutamide. — Wysowski DK, Freiman JP, Tourtelot JB, Horton ML Annals of internal medicine (1993)
    29. [29]
      Acute sulphasalazine hepatotoxicity. — Jennings PE, Blandford RL, Rosenthal FD Postgraduate medical journal (1986)
    30. [30]
      Vasculopathic hepatotoxicity associated with E-Ferol syndrome in low-birth-weight infants. — Bove KE, Kosmetatos N, Wedig KE, Frank DJ, Whitlatch S, Saldivar V et al. JAMA (1985)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG